The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome: The TICO Randomized Clinical Trial
Open accessAbstract
Importance: Discontinuing aspirin after short-term dual antiplatelet therapy (DAPT) was evaluated as a bleeding reduction strategy. However, the strategy of ticagrelor monotherapy has not been exclusively evaluated in patients with acute coronary syndromes (ACS). Objective: To determine whether switching to ticagrelor monotherapy after 3 months of DAPT reduces net adverse clinical events compared with ticagrelor-based 12-month DAPT in patients with ACS treated with drug-eluting stents. Design, Setting, and Participants: A randomized multicenter trial was conducted in 3056 patients with ACS treated with drug-eluting stents between August 2015 and October 2018 at 38 centers in South Korea. Follow-up was completed in October 2019. Interventions: Patients were randomized to receive ticagrelor monotherapy (90 mg twice daily) after 3-month DAPT (n = 1527) or ticagrelor-based 12-month DAPT (n = 1529). Main Outcomes and Measures: The primary outcome was a 1-year net adverse clinical event, defined as a composite of major bleeding and adverse cardiac and cerebrovascular events (death, myocardial infarction, stent thrombosis, stroke, or target-vessel revascularization). Prespecified secondary outcomes included major bleeding and major adverse cardiac and cerebrovascular events. Results: Among 3056 patients who were randomized (mean age, 61 years; 628 women [20%]; 36% ST-elevation myocardial infarction), 2978 patients (97.4%) completed the trial. The primary outcome occurred in 59 patients (3.9%) receiving ticagrelor monotherapy after 3-month DAPT and in 89 patients (5.9%) receiving ticagrelor-based 12-month DAPT (absolute difference, -1.98% [95% CI, -3.50% to -0.45%]; hazard ratio [HR], 0.66 [95% CI, 0.48 to 0.92]; P = .01). Of 10 prespecified secondary outcomes, 8 showed no significant difference. Major bleeding occurred in 1.7% of patients with ticagrelor monotherapy after 3-month DAPT and in 3.0% of patients with ticagrelor-based 12-month DAPT (HR, 0.56 [95% CI, 0.34 to 0.91]; P = .02). The incidence of major adverse cardiac and cerebrovascular events was not significantly different between the ticagrelor monotherapy after 3-month DAPT group (2.3%) vs the ticagrelor-based 12-month DAPT group (3.4%) (HR, 0.69 [95% CI, 0.45 to 1.06]; P = .09). Conclusions and Relevance: Among patients with acute coronary syndromes treated with drug-eluting stents, ticagrelor monotherapy after 3 months of dual antiplatelet therapy, compared with ticagrelor-based 12-month dual antiplatelet therapy, resulted in a modest but statistically significant reduction in a composite outcome of major bleeding and cardiovascular events at 1 year. The study population and lower than expected event rates should be considered in interpreting the trial. Trial Registration: ClinicalTrials.gov Identifier: NCT02494895.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ticagrelor versus clopidogrel in patients with acute coronary syndromes
Wallentin, L., Becker, R. C., Budaj, A., Cannon, C. P., Emanuelsson, H., Held, C., Horrow, J., Husted, S., James, S., Katus, H., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904327 · Cited by 7,117 · cited 1×
“Prior myocardial infarction 64 (4) 49 (3)”
Prasugrel versus clopidogrel in patients with acute coronary syndromes
Wiviott, S. D., Braunwald, E., McCabe, C. H., Montalescot, G., Ruzyllo, W., Gottlieb, S., Neumann, F.-J., Ardissino, D., De Servi, S., Murphy, S. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706482 · Cited by 6,790
Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions
Cutlip, D. E., Windecker, S., Mehran, R., Boam, A., Cohen, D. J., van Es, G.-A., Gabriel Steg, P., Morel, M.-A., Mauri, L., Vranckx, P., et al. (2007) · Circulation · doi:10.1161/circulationaha.106.685313 · Cited by 5,497
Mehran, R., Rao, S. V., Bhatt, D. L., Gibson, C. M., Caixeta, A., Eikelboom, J., Kaul, S., Wiviott, S. D., Menon, V., Nikolsky, E., et al. (2011) · Circulation · doi:10.1161/circulationaha.110.009449 · Cited by 4,476
Sacco, R. L., Kasner, S. E., Broderick, J. P., Caplan, L. R., Connors, J. J. (., Culebras, A., Elkind, M. S. V., George, M. G., Hamdan, A. D., Higashida, R. T., et al. (2013) · Stroke · doi:10.1161/str.0b013e318296aeca · Cited by 3,569
Valgimigli, M., Bueno, H., Byrne, R. A., Collet, J.-P., Costa, F., Jeppsson, A., Jüni, P., Kastrati, A., Kolh, P., Mauri, L., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx419 · Cited by 2,987
Third Universal Definition of Myocardial Infarction
Thygesen, K., Alpert, J. S., Jaffe, A. S., Simoons, M. L., Chaitman, B. R., & White, H. D. (2012) · Circulation · doi:10.1161/cir.0b013e31826e1058 · Cited by 2,985
Levine, G. N., Bates, E. R., Bittl, J. A., Brindis, R. G., Fihn, S. D., Fleisher, L. A., Granger, C. B., Lange, R. A., Mack, M. J., Mauri, L., et al. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.03.513 · Cited by 1,641
Ticagrelor with or without Aspirin in High-Risk Patients after PCI
Mehran, R., Baber, U., Sharma, S. K., Cohen, D. J., Angiolillo, D. J., Briguori, C., Cha, J. Y., Collier, T., Dangas, G., Dudek, D., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908419 · Cited by 1,039
Watanabe, H., Domei, T., Morimoto, T., Natsuaki, M., Shiomi, H., Toyota, T., Ohya, M., Suwa, S., Takagi, K., Nanasato, M., et al. (2019) · JAMA · doi:10.1001/jama.2019.8145 · Cited by 857
Self-citationVranckx, P., Valgimigli, M., Jüni, P., Hamm, C., Steg, P. G., Heg, D., van Es, G. A., McFadden, E. P., Onuma, Y., van Meijeren, C., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31858-0 · Cited by 791
A New Strategy for Discontinuation of Dual Antiplatelet Therapy
Kim, B.-K., Hong, M.-K., Shin, D.-H., Nam, C.-M., Kim, J.-S., Ko, Y.-G., Choi, D., Kang, T.-S., Park, B.-E., Kang, W.-C., et al. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.06.043 · Cited by 646
Self-citationHahn, J.-Y., Song, Y. B., Oh, J.-H., Chun, W. J., Park, Y. H., Jang, W. J., Im, E.-S., Jeong, J.-O., Cho, B. R., Oh, S. K., et al. (2019) · JAMA · doi:10.1001/jama.2019.8146 · Cited by 623
Self-citationFeres, F. (2013) · JAMA · doi:10.1001/jama.2013.282183 · Cited by 589
Palmerini, T., Benedetto, U., Bacchi-Reggiani, L., Riva, D. D., Biondi-Zoccai, G., Feres, F., Abizaid, A., Hong, M.-K., Kim, B.-K., Jang, Y., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60263-x · Cited by 396
Self-citationBecker, R. C., Bassand, J. P., Budaj, A., Wojdyla, D. M., James, S. K., Cornel, J. H., French, J., Held, C., Horrow, J., Husted, S., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr422 · Cited by 383
Hahn, J.-Y., Song, Y. B., Oh, J.-H., Cho, D.-K., Lee, J. B., Doh, J.-H., Kim, S.-H., Jeong, J.-O., Bae, J.-H., Kim, B.-O., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30493-8 · Cited by 372
Self-citationAntman, E. M., Wiviott, S. D., Murphy, S. A., Voitk, J., Hasin, Y., Widimsky, P., Chandna, H., Macias, W., McCabe, C. H., & Braunwald, E. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.04.002 · Cited by 328
Kandzari, D. E., Mauri, L., Koolen, J. J., Massaro, J. M., Doros, G., Garcia-Garcia, H. M., Bennett, J., Roguin, A., Gharib, E. G., Cutlip, D. E., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32249-3 · Cited by 279
Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention
Capodanno, D., Mehran, R., Valgimigli, M., Baber, U., Windecker, S., Vranckx, P., Dangas, G., Rollini, F., Kimura, T., Collet, J.-P., et al. (2018) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0049-1 · Cited by 214
Park, D.-W., Kwon, O., Jang, J.-S., Yun, S.-C., Park, H., Kang, D.-Y., Ahn, J.-M., Lee, P. H., Lee, S.-W., Park, S.-W., et al. (2019) · Circulation · doi:10.1161/circulationaha.119.041766 · Cited by 208
Iglesias, J. F., Muller, O., Heg, D., Roffi, M., Kurz, D. J., Moarof, I., Weilenmann, D., Kaiser, C., Tapponnier, M., Stortecky, S., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31877-x · Cited by 188
De Luca, G., Damen, S. A., Camaro, C., Benit, E., Verdoia, M., Rasoul, S., Liew, H. B., Polad, J., Ahmad, W. A., Zambahari, R., et al. (2019) · EuroIntervention · doi:10.4244/eij-d-19-00539 · Cited by 187
Kedhi, E., Fabris, E., van der Ent, M., Buszman, P., von Birgelen, C., Roolvink, V., Zurakowski, A., Schotborgh, C. E., Hoorntje, J. C. A., Eek, C. H., et al. (2018) · BMJ · doi:10.1136/bmj.k3793 · Cited by 184
Hong, S., Shin, D., Kim, J., Kim, B., Ko, Y., Choi, D., Her, A., Kim, Y. H., Jang, Y., & Hong, M. (2016) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2016.04.036 · Cited by 139
Self-citationKaul, S., & Diamond, G. A. (2006) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2006.10.001 · Cited by 38
Kim, C., Hong, S., Shin, D., Kim, B., Ahn, C., Kim, J., Ko, Y., Choi, D., Hong, M., & Jang, Y. (2019) · American Heart Journal · doi:10.1016/j.ahj.2019.02.015 · Cited by 34
Self-citationLee, S., Hong, M., Shin, D., Kim, J., Kim, B., Ko, Y., Choi, D., Jang, Y., Kim, H.-S., Valgimigli, M., et al. (2016) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.116.004256 · Cited by 15
Self-citation
Cited by
2023 ESC Guidelines for the management of acute coronary syndromes
Byrne, R. A., Rossello, X., Coughlan, J. J., Barbato, E., Berry, C., Chieffo, A., Claeys, M. J., Dan, G.-A., Dweck, M. R., Galbraith, M., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad191 · Cited by 5,333
Virani, S. S., Newby, L. K., Arnold, S. V., Bittner, V., Brewer, L. C., Demeter, S. H., Dixon, D. L., Fearon, W. F., Hess, B., Johnson, H. M., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001168 · Cited by 1,598
2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization
Lawton, J. S., Tamis-Holland, J. E., Bangalore, S., Bates, E. R., Beckie, T. M., Bischoff, J. M., Bittl, J. A., Cohen, M. G., DiMaio, J. M., Don, C. W., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.09.006 · Cited by 1,558
Lawton, J. S., Tamis-Holland, J. E., Bangalore, S., Bates, E. R., Beckie, T. M., Bischoff, J. M., Bittl, J. A., Cohen, M. G., DiMaio, J. M., Don, C. W., et al. (2022) · Circulation · doi:10.1161/cir.0000000000001038 · Cited by 829
Lawton, J. S., Tamis-Holland, J. E., Bangalore, S., Bates, E. R., Beckie, T. M., Bischoff, J. M., Bittl, J. A., Cohen, M. G., DiMaio, J. M., Don, C. W., et al. (2022) · Circulation · doi:10.1161/cir.0000000000001039 · Cited by 641
Metadata
- Authors
- Kim, B.-K., Hong, S.-J., Cho, Y.-H., Yun, K. H., Kim, Y. H., Suh, Y., Cho, J. Y., Her, A.-Y., Cho, S., Jeon, D. W., Yoo, S.-Y., Cho, D.-K., Hong, B.-K., Kwon, H., Ahn, C.-M., Shin, D.-H., Nam, C.-M., Kim, J.-S., Ko, Y.-G., Choi, D., Hong, M.-K., Jang, Y., & for the TICO Investigators
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2020-06-16
- Volume
- 323
- Issue
- 23
- Pages
- 2407
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W3035351100
- Cited by
- 588
- References
- 28
- FWCI
- 46.65
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.